Shenzhen Chipscreen Biosciences Co - Asset Resilience Ratio
Shenzhen Chipscreen Biosciences Co (688321) has an Asset Resilience Ratio of 5.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Shenzhen Chipscreen Biosciences Co to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Shenzhen Chipscreen Biosciences Co's Asset Resilience Ratio has changed over time. See net asset quality index of Shenzhen Chipscreen Biosciences Co to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Chipscreen Biosciences Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Shenzhen Chipscreen Biosciences Co.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥185.25 Million | 5.1% |
| Total Liquid Assets | CN¥185.25 Million | 5.10% |
Asset Resilience Insights
- Limited Liquidity: Shenzhen Chipscreen Biosciences Co maintains only 5.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Chipscreen Biosciences Co Industry Peers by Asset Resilience Ratio
Compare Shenzhen Chipscreen Biosciences Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Shenzhen Chipscreen Biosciences Co (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Shenzhen Chipscreen Biosciences Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.90% | CN¥94.13 Million ≈ $13.77 Million |
CN¥3.25 Billion ≈ $475.71 Million |
-3.87pp |
| 2023-12-31 | 6.77% | CN¥216.72 Million ≈ $31.71 Million |
CN¥3.20 Billion ≈ $468.74 Million |
-3.29pp |
| 2022-12-31 | 10.05% | CN¥291.07 Million ≈ $42.59 Million |
CN¥2.90 Billion ≈ $423.75 Million |
+5.72pp |
| 2021-12-31 | 4.33% | CN¥82.08 Million ≈ $12.01 Million |
CN¥1.89 Billion ≈ $277.21 Million |
-10.84pp |
| 2020-12-31 | 15.17% | CN¥261.87 Million ≈ $38.32 Million |
CN¥1.73 Billion ≈ $252.61 Million |
+14.93pp |
| 2019-12-31 | 0.24% | CN¥4.02 Million ≈ $588.49K |
CN¥1.69 Billion ≈ $247.51 Million |
-5.60pp |
| 2018-12-31 | 5.84% | CN¥41.83 Million ≈ $6.12 Million |
CN¥716.34 Million ≈ $104.82 Million |
-19.75pp |
| 2017-12-31 | 25.59% | CN¥167.86 Million ≈ $24.56 Million |
CN¥656.02 Million ≈ $96.00 Million |
+0.41pp |
| 2016-12-31 | 25.18% | CN¥101.49 Million ≈ $14.85 Million |
CN¥403.13 Million ≈ $58.99 Million |
-- |
About Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more